Protagonist Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	281.99	46.02	434.43	60	26.58	27.36
Revenue Growth	34.81%	-89.41%	624.05%	125.72%	-2.84%	-4.44%
Gross Profit	281.99	46.02	434.43	60	26.58	27.36
Selling, General & Admin	48.49	44.85	43.46	33.49	31.74	27.2
Research & Development	175.16	159.29	138.13	120.16	126.22	126.01
Operating Expenses	223.65	204.14	181.59	153.65	157.95	153.2
Operating Income	58.34	-158.13	252.84	-93.65	-131.37	-125.85
Interest & Investment Income	26.12	28.79	26.32	14.9	4.06	0.44
Currency Exchange Gain (Loss)	-	-	-	-	-0.08	-0.15
Other Non Operating Income (Expenses)	-0.13	0.03	0.25	-0.2	-	-
EBT Excluding Unusual Items	84.33	-129.31	279.41	-78.96	-127.39	-125.55
Pretax Income	84.34	-129.31	279.41	-78.96	-127.39	-125.55
Income Tax Expense	1.43	0.84	4.22	-	-	-
Net Income	82.91	-130.15	275.19	-78.96	-127.39	-125.55
Net Income to Common	82.91	-130.15	275.19	-78.96	-127.39	-125.55
Net Income Growth	59.32%	-	-	-	-	-
Shares Outstanding (Basic)	65	64	62	57	49	46
Shares Outstanding (Diluted)	67	64	65	57	49	46
Shares Change	4.05%	-2.31%	14.65%	15.74%	5.87%	34.67%
EPS (Basic)	1.28	-2.05	4.47	-1.39	-2.60	-2.71
EPS (Diluted)	1.22	-2.05	4.23	-1.39	-2.60	-2.71
EPS Growth	51.80%	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	130.58	56.08	182.8	-70.85	-108.93	-108.97
Free Cash Flow Per Share	1.94	0.88	2.81	-1.25	-2.22	-2.35
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	20.69%	-343.63%	58.20%	-156.09%	-494.24%	-460.01%
Profit Margin	29.40%	-282.83%	63.34%	-131.59%	-479.26%	-458.94%
Free Cash Flow Margin	46.31%	121.87%	42.08%	-118.08%	-409.81%	-398.31%
EBITDA	59.88	-156.85	253.67	-92.68	-130.34	-125.03
EBITDA Margin	21.24%	-	58.39%	-154.46%	-	-
D&A For EBITDA	1.54	1.28	0.83	0.98	1.03	0.81
EBIT	58.34	-158.13	252.84	-93.65	-131.37	-125.85
EBIT Margin	20.69%	-	58.20%	-156.09%	-	-
Effective Tax Rate	1.69%	-	1.51%	-	-	-

SEC Filings: 10-K · 10-Q